Bristol-Myers Squibb could be in a position to launch ipilimumab for the treatment of second-line metastatic melanoma early next year if the recently submitted drug is granted a priority review by regulators. The company announced during a second quarter earnings call July 22 that it submitted regulatory filings for ipilimumab with both the U.S. FDA and European Medicines Agency at the end of June.Approval of the cytotoxic T lymphocyte antigen-4 inhibitor seems likely based on a Phase III trial showing...